Country by country molecule assessment in minutes, not days.
Molecule Opportunity Assessment
Before
Days per assessment
Now
Minutes
The challenge
Emerging biopharma teams evaluating molecule opportunities faced slow, expensive and static market research. Changing a therapy area, a dosage form or a target geography meant days of waiting, which made real scenario analysis impossible.
What we built
Six analytical modules running in sequence: market sizing, opportunity scoring per country, competitive white space, revenue scenario modelling, portfolio synergy detection and market entry assessment. Results arrive as heat maps, scenario models and written narratives.
How it runs
- SizeMarket sizing and forecasting by geography
- ScoreOpportunity scored 0 to 100 for each country
- ModelBest, base and worst case revenue scenarios
The result
- Minutes
- Per market assessment
- 6
- Analytical modules
- 0 to 100
- Country opportunity score
Built with
- Market sizing
- Scenario modelling
- AI narratives
Run this in Pharma & Life Sciences
The same Decision support build, scoped to your sources and your reporting lines.